


WHAT IS CLAIMED IS:

1. A compound having the structure of Formula I:



wherein

Ar₁ is selected from the group consisting of a monocyclic heteroaromatic ring structure and a bicyclic heteroaromatic ring structure;

Ar₂ is selected from the group consisting of a monocyclic, a bicyclic, and a tricyclic carbocyclic aryl ring structure

R₁ is selected from the group consisting of

alkyl, optionally substituted with a substituent selected from the group consisting of hydrogen, lower alkyl, optionally substituted carbocyclic or heterocyclic ring, halogen, perhaloalkyl, hydroxy, alkoxy, nitro, and amino;

a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, optionally substituted with one or more substituents selected from the group consisting of optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl; an alkoxy; cyano; nitro; an amino; an amido; perhaloalkyl; and halogen;

R₂ is selected from the group consisting of

hydrogen;

alkyl, optionally substituted with a substituent selected from the group consisting of hydrogen, lower alkyl, optionally substituted carbocyclic or heterocyclic ring, halogen, perhaloalkyl, hydroxy, alkoxy, nitro, and amino;

a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, optionally substituted with one or more substituents selected from the group consisting of optionally substituted C₁-C₈ straight-chain, branched, or cyclic saturated or unsaturated alkyl; an alkoxy; halogen; and perhaloalkyl; cyano; nitro; an amino; an amido; perhaloalkyl; and halogen;

R_3 is selected from the group consisting of hydrogen; alkyl, optionally substituted with a substituent selected from the group consisting of hydrogen, lower alkyl, optionally substituted carbocyclic or heterocyclic ring; hydroxy; halogen; amino; nitro; and cyano; and

B is a five-membered or six-membered heteroaryl ring, or $-(CH_2)_j-C(O)OR_4$, wherein j is 0 or 1 when Ar_2 is a bicyclic or tricyclic carbocyclic ring structure and j is 1 when Ar_2 is a monocyclic carbocyclic ring structure; and

R_4 is selected from the group consisting of

hydrogen;

alkyl, optionally substituted with a substituent selected from the group consisting of

hydrogen, lower alkyl, optionally substituted carbocyclic or heterocyclic ring;


a five-membered or six-membered heteroaryl ring or a six-membered aryl ring, optionally substituted with one or more substituents selected from the group consisting of optionally substituted C_1 - C_8 straight-chain, branched, or cyclic saturated or unsaturated alkyl;

or a pharmaceutically acceptable N-oxide, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

2. The compound of Claim 1, wherein Ar_2 is selected from the group consisting of phenyl, naphthyl, anthracene, and phenanthrene.

3. The compound of Claim 2, wherein Ar_2 is phenyl.

4. The compound of Claim 3, having the structure:



5. The compound of claim 2, wherein Ar_2 is naphthyl.

6. The compound of Claim 4 or Claim 5, wherein R_1 is alkyl, optionally substituted with one or more optionally substituted carbocyclic or heterocyclic rings.

7. The compound of Claim 6, wherein said alkyl is a lower alkyl.

8. The compound of Claim 7, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.

9. The compound of Claim 6, wherein said carbocyclic ring is phenyl.

10. The compound of Claim 9, wherein said phenyl is optionally substituted with one or more substituents selected from the group consisting of lower alkyl, halogen, perhaloalkyl, hydroxy, alkoxy, nitro, and amino.





11. The compound of Claim 10, wherein said substituent is perhaloalkyl.


12. The compound of Claim 11, wherein said perhaloalkyl is trifluoromethyl.

13. The compound of Claim 1, wherein R_1 is alkyl substituted with 4-bis(trifluoromethyl)phenylmethyl.


14. The compound of Claim 1, wherein Ar_1 is a nitrogen-containing or oxygen-containing heterocycle.

15. The compound of Claim 14, wherein Ar_1 is selected from the group consisting of furan, thiophene, pyrrole, pyrroline, pyrrolidine, oxazole, thiazole, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, pyran, pyridine, piperidine, morpholine, thiomorpholine, pyridazine, pyrimidine,

pyrazine, piperazine, triazine, , , , , and



16. The compound of Claim 15, wherein Ar_1 is pyridine, pyrimidine,



17. The compound of Claim 16, wherein Ar_1 is pyrimidine.

18. The compound of any of Claim 4 and Claim 5, wherein R_2 is optionally substituted alkyl.

19. The compound of Claim 18, wherein said alkyl is a lower alkyl.

20. The compound of Claim 19, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.

21. The compound of any of Claim 20, wherein R_2 is ethyl.

22. The compound of Claim 1, wherein R_3 is hydrogen, halogen or optionally substituted alkyl.

23. The compound of Claim 22, wherein said optionally substituted alkyl is an optionally substituted lower alkyl.

24. The compound of Claim 23, wherein said optionally substituted lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.

25. The compound of Claim 1, wherein R_3 is methyl.



26. The compound of Claim 1, wherein R_3 is hydrogen.

27. The compound of Claim 1, wherein B and the propyloxy substituents on Ar_2 are ortho to each other.

28. The compound of Claim 1, wherein B and the propyloxy substituents on Ar_2 are meta to each other.

29. The compound of Claim 1, wherein B and the propyloxy substituents on Ar_2 are para to each other.


30. The compound of Claim 1, wherein B is a heteroaryl ring selected from the group consisting of furan, thiophene, pyrrole, pyrroline, pyrrolidine, oxazole, thiazole, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, pyran, pyridine, piperidine, morpholine, thiomorpholine, pyridazine, pyrimidine, pyrazine, piperazine, triazine,




31. The compound of Claim 30, wherein B is a tetrazole.

32. The compound of Claim 1, wherein B is $-(CH_2)_j-C(O)OR_4$.


33. The compound of Claim 32, wherein R_4 is hydrogen or optionally substituted alkyl.
34. The compound of Claim 33, wherein said alkyl is a lower alkyl.
35. The compound of Claim 34, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.
36. The compound of Claim 33, wherein R_4 is hydrogen.
37. The compound of any of Claim 4 and Claim 5, wherein Ar_1 is a nitrogen-containing or oxygen-containing heterocycle.
38. The compound of Claim 37, wherein Ar_1 is selected from the group consisting of furan, thiophene, pyrrole, pyrroline, pyrrolidine, oxazole, thiazole, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, pyran, pyridine, piperidine, morpholine, thiomorpholine, pyridazine, pyrimidine,




39. The compound of Claim 38, wherein Ar_1 is pyridine, pyrimidine,




40. The compound of Claim 39, wherein Ar_1 is pyrimidine.
41. The compound of any of Claim 4 and Claim 5, wherein B is a heteroaryl ring selected from the group consisting of furan, thiophene, pyrrole, pyrroline, pyrrolidine, oxazole, thiazole, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, pyran, pyridine, piperidine, morpholine,



thiomorpholine, pyridazine, pyrimidine, pyrazine, piperazine, triazine,




42. The compound of Claim 41, wherein B is a tetrazole.
43. The compound of any of Claim 4 and Claim 5, wherein B is $-(CH_2)_j-C(O)OR_4$.
44. The compound of Claim 43, wherein R_4 is hydrogen or optionally substituted alkyl.
45. The compound of Claim 44, wherein said alkyl is a lower alkyl.
46. The compound of Claim 45, wherein said lower alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.
47. The compound of any of Claim 4 and Claim 5, wherein R_4 is hydrogen.
48. The compound of Claim 4 selected from the group consisting of:




or a pharmaceutically acceptable N-oxide, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

49. The compound of Claim 5 selected from the group consisting of



pharmaceutically acceptable N-oxide, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, pharmaceutically acceptable amide, or pharmaceutically acceptable solvate thereof.

50. A compound having the structure of Formula III:



51. A method of modulating a peroxisome proliferator-activated receptor (PPAR) function comprising contacting said PPAR with a compound of Claim 1 and monitoring a change in cell phenotype, cell proliferation, activity of said PPAR, or binding of said PPAR with a natural binding partner.

52. The method of Claim 51, wherein said PPAR is selected from the group consisting of PPAR α , PPAR δ , and PPAR γ .

53. A method of inhibiting the formation of adipocytes in a mammal comprising administering a therapeutically effective amount of a compound of Claim 1 to the mammal.

54. The method of Claim 53, comprising administering a therapeutically effective amount of a compound of Claim 3 to the mammal.

55. The method of Claim 54, comprising administering a therapeutically effective amount of a compound of Claim 4 to the mammal.

56. The method of Claim 53, comprising administering a therapeutically effective amount of a compound of Claim 5 to the mammal.

57. A method of inhibiting the formation of adipocytes in a mammal comprising administering a therapeutically effective amount of a compound of Claim 50 to the mammal.

58. A method of treating a disease comprising identifying a patient in need thereof, and administering a therapeutically effective amount of a compound of Claim 1 to the patient.

59. The method of Claim 58, wherein the disease is a PPAR-modulated disease or condition.

60. The method of Claim 58, wherein the disease is a metabolic disorder or condition.

61. The method of Claim 58, wherein said disease is selected from the group consisting of obesity, diabetes, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, climacteric, disorders associated with oxidative stress, inflammatory response to tissue injury, pathogenesis of emphysema, ischemia-associated organ injury, doxorubicin-induced cardiac injury, drug-induced hepatotoxicity, atherosclerosis, and hypertoxic lung injury.

62. The method of any of Claims 59-61, comprising administering a therapeutically effective amount of a compound of Claim 3 to said mammal.

63. The method of any of Claims 59-61, comprising administering a therapeutically effective amount of a compound of Claim 4 to said mammal.

64. The method of any of Claims 59-61, comprising administering a therapeutically effective amount of a compound of Claim 5 to said mammal.

65. A method of treating a PPAR-modulated disease or condition comprising identifying a patient in need thereof, and administering a therapeutically effective amount of the compound of Claim 50 to the patient.

66. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable diluent, excipient, or carrier.

67. A pharmaceutical composition comprising a compound of Claim 3 and a pharmaceutically acceptable diluent, excipient, or carrier.

68. A pharmaceutical composition comprising a compound of Claim 4 and a pharmaceutically acceptable diluent, excipient, or carrier.

69. A pharmaceutical composition comprising a compound of Claim 5 and a pharmaceutically acceptable diluent, excipient, or carrier.

70. A pharmaceutical composition comprising the compound of Claim 50 and a pharmaceutically acceptable diluent, excipient, or carrier.